TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

by · The Markets Daily

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX – Get Free Report) have received a consensus rating of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $50.25.

A number of equities analysts have issued reports on TGTX shares. Weiss Ratings restated a “hold (c+)” rating on shares of TG Therapeutics in a research report on Monday. B. Riley raised TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. HC Wainwright started coverage on TG Therapeutics in a report on Monday, October 6th. They set a “buy” rating and a $60.00 price target on the stock. Wall Street Zen raised TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, December 14th. Finally, JPMorgan Chase & Co. increased their price objective on TG Therapeutics from $46.00 to $49.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd.

Check Out Our Latest Stock Analysis on TGTX

TG Therapeutics Price Performance

Shares of TG Therapeutics stock opened at $29.81 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.82 and a quick ratio of 2.89. TG Therapeutics has a one year low of $25.28 and a one year high of $46.48. The business’s 50 day simple moving average is $31.71 and its two-hundred day simple moving average is $33.04. The stock has a market capitalization of $4.73 billion, a P/E ratio of 10.72 and a beta of 1.86.

TG Therapeutics (NASDAQ:TGTX – Get Free Report) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $2.19. TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. The firm had revenue of $161.71 million for the quarter, compared to analysts’ expectations of $152.12 million. During the same quarter last year, the business earned $0.02 earnings per share. The business’s revenue was up 92.7% on a year-over-year basis. Analysts forecast that TG Therapeutics will post 0.08 EPS for the current year.

Insider Buying and Selling

In related news, Director Yann Echelard sold 5,000 shares of TG Therapeutics stock in a transaction on Monday, November 24th. The shares were sold at an average price of $32.57, for a total value of $162,850.00. Following the sale, the director owned 223,816 shares in the company, valued at $7,289,687.12. The trade was a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 10.64% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. HighTower Advisors LLC boosted its stake in shares of TG Therapeutics by 53.5% during the 1st quarter. HighTower Advisors LLC now owns 22,891 shares of the biopharmaceutical company’s stock valued at $903,000 after purchasing an additional 7,979 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in TG Therapeutics by 26.8% during the 1st quarter. Smartleaf Asset Management LLC now owns 2,416 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 511 shares in the last quarter. SVB Wealth LLC purchased a new position in shares of TG Therapeutics during the 1st quarter worth approximately $37,000. Jump Financial LLC bought a new position in shares of TG Therapeutics in the 1st quarter worth approximately $1,936,000. Finally, Driehaus Capital Management LLC purchased a new position in shares of TG Therapeutics in the 1st quarter valued at approximately $30,545,000. 58.58% of the stock is currently owned by institutional investors.

TG Therapeutics Company Profile

(Get Free Report)

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.

Read More